This educational session will introduce CCM® therapy through the eyes of implanting electrophysiologists. Also discussed, the updated FDA Labeling for indications for use that read: The OPTIMIZER® System, which delivers Cardiac Contractility Modulation(CCM) therapy, is indicated to improve 6-minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline directed medical therapy, are not receiving Cardiac Resynchronization Therapy (CRT), and have a left ventricular ejection fraction ranging from 25%-45%. Using their own clinical cases, program faculty will discuss the screening process for eligible CCM® patients, the implant procedure, lead placement, and patient follow-up. Both faculty members will share their personal experience with CCM® and individual patient responses to the therapy.